{
    "organizations": [],
    "uuid": "6e2cbaca475206f02651e1a03114181eddbf0245",
    "author": "",
    "url": "https://www.reuters.com/article/brief-egalet-says-received-notice-from-t/brief-egalet-says-received-notice-from-teva-pharmaceuticals-usa-of-anda-submission-for-approval-to-market-generic-version-of-arymo-er-extended-release-tablets-idUSFWN1QD1HO",
    "ord_in_thread": 0,
    "title": "BRIEF-Egalet Says Received Notice From Teva Pharmaceuticals USA Of ANDA Submission For Approval To Market Generic Version Of Arymo ER Extended-Release Tablets",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 23 (Reuters) - Egalet Corp:\n* EGALET - CO, UNIT RECEIVED NOTICE FROM TEVA PHARMACEUTICALS USA OF ANDA SUBMISSION FOR APPROVAL TO MARKET GENERIC VERSION OF ARYMO ER EXTENDED-RELEASE TABLETS\n* EGALET SAYS CURRENTLY REVIEWING DETAILS OF TEVAâ€™S NOTICE, PARAGRAPH IV CERTIFICATION - SEC FILING Source text: ( bit.ly/2FqX1Lp ) Further company coverage:\n ",
    "published": "2018-02-24T00:39:00.000+02:00",
    "crawled": "2018-02-24T00:54:53.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "egalet",
        "corp",
        "egalet",
        "co",
        "unit",
        "received",
        "notice",
        "teva",
        "pharmaceutical",
        "usa",
        "anda",
        "submission",
        "approval",
        "market",
        "generic",
        "version",
        "arymo",
        "er",
        "tablet",
        "egalet",
        "say",
        "currently",
        "reviewing",
        "detail",
        "teva",
        "notice",
        "paragraph",
        "iv",
        "certification",
        "sec",
        "filing",
        "source",
        "text",
        "company",
        "coverage"
    ]
}